Miqnaf is an antibiotic for treatment of community-acquired bacterial pneumonia, including those caused by multi-drug ...

Wockhardt's novel antibiotic Miqnaf approved for CABP treatment, offering a promising monotherapy option for MDR pathogens.

Adapted from Ramirez JA, Srinath L, Ahkee S, et al: Early switch from intravenous to oral cephalosporins in the treatment of hospitalized patients with community-acquired pneumonia. Arch Intern ...

HMPV causes mild illness in most adults. However, it poses a higher risk to specific vulnerable groups. These people need to ...

Srishty Rode a renowned TV actress shares her experience of being hospitalised during her Europe trip due to pneumonia Read ...

Central Drugs Standard Control Organization (CDSCO) approved antibiotic Nafithromycin, sold under Miqnaf brand, as a new treatment for community-acquired bacterial Pneumonia (CABP) in adults.

Walking pneumonia differs from other respiratory infections like flu or cold because it quickly settles in the chest and can leave people feeling short of breath. With walking pneumonia, any ...

Following recent HMPV confirmations in Karnataka, Tamil Nadu, and Gujarat, seven total cases have been reported in India, ...

There is no role of antibiotics in treating the Human Metapneumovirus (HMPV), a respiratory illness currently seeing an ...

Without treatment, bronchitis can become pneumonia. You’re coughing ... is treated by addressing the source of the infection. Antibiotics may be used to treat a bacterial cause, while antivirals ...

Wockhardt rallied 6.60% to Rs 1,541.15 after the Central Drugs Standard Control Organization (CDSCO) has approved Miqnaf (nafithromycin) as a new treatment for the community-acquired bacterial ...